Let’s talk TOC and conductivity requirements for pharmaceutical water systems

When it comes to medical product discovery, development, and delivery, patients need to be front and center but how close (or far away) are we from truly having a system that routinely measures what matters to patients? A panel of industry, regulatory, and patient leaders will discuss what’s next for patient-centered measurement. Panelists will define patient-centered measurement; identify novel strategies for capturing patient-centered outcomes; assess the progress in product development, regulatory approval, and delivery; and address how to advance the science of patient input in a way that fulfills the unmet needs of patients across diseases.

Fibrotic diseases of the heart and liver impact a significant portion of the global population and are a growing public health concern. Fibrosis occurs when fibroblasts deposit excess extracellular material within the tissue in response to certain stimuli or injury. Myocardial fibrosis is associated with nearly all forms of heart disease. The pathological changes that can result from fibrosis include cardiomyocyte hypertrophy, chamber dilation, heart valve stiffening, and others, all of which contribute to heart failure. Nonalcoholic steatohepatitis (NASH) is a fatty liver disease characterized by hepatocyte inflammation that contributes to fibrosis, cirrhosis, and liver failure. NASH is closely linked to obesity and diabetes; changes in diet have thus contributed to its expansion and impact across the globe. Understanding the underlying biology of fibrosis is critical for the diagnosis, treatment, and management of cardiac fibrosis, NASH, and other fibrotic diseases.

With financial resiliency efforts, budget constraints, and staffing shortages likely to continue, 2023 could be the year when the operational efficiencies that result from partial IT outsourcing is one of your best options for staying on track with the technology innovations your healthcare organization needs.

Worldwide, there is a growing appeal in the pharmaceutical industry for recombinant technologies that help alleviate, and eventually replace, the use of animal resources for endotoxin testing purposes.